EA200400815A1 - Контролируемый синтез зипразидона и его композиции - Google Patents
Контролируемый синтез зипразидона и его композицииInfo
- Publication number
- EA200400815A1 EA200400815A1 EA200400815A EA200400815A EA200400815A1 EA 200400815 A1 EA200400815 A1 EA 200400815A1 EA 200400815 A EA200400815 A EA 200400815A EA 200400815 A EA200400815 A EA 200400815A EA 200400815 A1 EA200400815 A1 EA 200400815A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compositions
- ziprazidona
- controlled synthesis
- undechloroziprasidone
- synthesis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Согласно данному изобретению предложена композиция зипразидона, содержащая не более 1000 млндехлорзипразидона, предпочтительно не более чем приблизительно 500 млндехлорзипразидона и более предпочтительно не более чем приблизительно 100 млндехлорзипразидона. Также предложены способы синтеза и применения таких композиций зипразидона.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35880602P | 2002-02-20 | 2002-02-20 | |
US35903802P | 2002-02-21 | 2002-02-21 | |
US36045902P | 2002-02-27 | 2002-02-27 | |
PCT/IB2003/000642 WO2003070246A1 (en) | 2002-02-20 | 2003-02-17 | Controlled synthesis of ziprasidone and compositions thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200400815A1 true EA200400815A1 (ru) | 2004-12-30 |
EA007866B1 EA007866B1 (ru) | 2007-02-27 |
Family
ID=27761437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200400815A EA007866B1 (ru) | 2002-02-20 | 2003-02-17 | Контролируемый синтез зипразидона и его композиции |
Country Status (41)
Country | Link |
---|---|
EP (1) | EP1476162B1 (ru) |
JP (1) | JP4554938B2 (ru) |
KR (1) | KR100773622B1 (ru) |
CN (2) | CN101735212A (ru) |
AP (1) | AP2004003103A0 (ru) |
AR (1) | AR038563A1 (ru) |
AT (1) | ATE359787T1 (ru) |
AU (2) | AU2003206035A1 (ru) |
BR (1) | BR0307833A (ru) |
CA (1) | CA2475302C (ru) |
CO (1) | CO5611138A2 (ru) |
CY (1) | CY1106467T1 (ru) |
DE (1) | DE60313289T2 (ru) |
DK (1) | DK1476162T3 (ru) |
EA (1) | EA007866B1 (ru) |
EC (1) | ECSP045239A (ru) |
ES (1) | ES2283745T3 (ru) |
GE (1) | GEP20074030B (ru) |
GT (1) | GT200300040A (ru) |
HR (1) | HRP20040711A2 (ru) |
IL (1) | IL163277A (ru) |
IS (1) | IS7344A (ru) |
MA (1) | MA27177A1 (ru) |
MX (1) | MXPA04006993A (ru) |
MY (1) | MY139523A (ru) |
NO (2) | NO20043902L (ru) |
NZ (1) | NZ534443A (ru) |
OA (1) | OA12774A (ru) |
PA (1) | PA8567001A1 (ru) |
PE (1) | PE20030942A1 (ru) |
PL (1) | PL372238A1 (ru) |
PT (1) | PT1476162E (ru) |
RS (1) | RS60404A (ru) |
SI (1) | SI1476162T1 (ru) |
SV (1) | SV2004001485A (ru) |
TN (1) | TNSN04159A1 (ru) |
TW (1) | TW200307546A (ru) |
UA (1) | UA77057C2 (ru) |
UY (1) | UY27668A1 (ru) |
WO (1) | WO2003070246A1 (ru) |
ZA (1) | ZA200406276B (ru) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100879647B1 (ko) | 2000-03-06 | 2009-01-20 | 아카디아 파마슈티칼스 인코포레이티드 | 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물 |
MXPA04006280A (es) | 2001-12-28 | 2004-09-27 | Acadia Pharm Inc | Compuestos espiroazaciclicos como moduladores de receptor de monoamina. |
AU2003247615B2 (en) | 2002-06-24 | 2007-08-09 | Acadia Pharmaceuticals Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
WO2004050655A1 (en) * | 2002-12-04 | 2004-06-17 | Dr. Reddy's Laboratories Limited | Polymorphic forms of ziprasidone and its hydrochloride |
AU2003300814A1 (en) | 2002-12-04 | 2004-06-23 | Dr. Reddy's Laboratories Inc. | Polymorphic forms of ziprasidone and its hydrochloride |
ES2314362T3 (es) | 2003-01-16 | 2009-03-16 | Acadia Pharmaceuticals Inc. | Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilizados como agentes terapeuticos contra enfermedades neurodegenerativas. |
US7199144B2 (en) | 2003-04-21 | 2007-04-03 | Teva Pharmaceuticals Industries, Ltd. | Process for the preparation of valsartan and intermediates thereof |
DE602004013405T2 (de) | 2003-03-17 | 2009-05-07 | Teva Pharmaceutical Industries Ltd. | Polymorphe formen von valsartan |
EP1618097A1 (en) | 2003-04-21 | 2006-01-25 | Teva Pharmaceutical Industries Ltd | Process for the preparation of valsartan |
KR20080093164A (ko) | 2003-06-03 | 2008-10-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 결정성 지프라시돈 염산염 및 그의 제조 방법 |
US7667037B2 (en) | 2003-10-24 | 2010-02-23 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of ziprasidone |
EP1592688A2 (en) * | 2003-12-18 | 2005-11-09 | Teva Pharmaceutical Industries Ltd. | Polymorphic form b2 of ziprasidone base |
PT1720867E (pt) | 2004-02-27 | 2010-01-28 | Ranbaxy Lab Ltd | Processo para a preparação de ziprasidona |
CA2467538C (en) | 2004-05-14 | 2010-08-24 | Apotex Pharmachem Inc. | New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same |
US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
CA2471219A1 (en) | 2004-06-14 | 2005-12-14 | Apotex Pharmachem Inc. | Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) |
US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
CN101031548B (zh) | 2004-09-27 | 2011-04-06 | 阿卡蒂亚药品公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备 |
ES2250001B1 (es) * | 2004-09-29 | 2007-06-01 | Medichem, S.A. | Proceso para la purificacion de ziprasidona. |
ES2250000B1 (es) * | 2004-09-29 | 2007-06-01 | Medichem, S.A. | Procedimiento para la preparacion de ziprasidona. |
WO2006080025A1 (en) * | 2005-01-27 | 2006-08-03 | Hetero Drugs Limited | Process for ziprasidone using novel intermediates |
ITMI20052216A1 (it) * | 2005-11-18 | 2007-05-19 | Dipharma Spa | Procedimento per la preparazione di ziprasidone |
CN100491375C (zh) * | 2006-07-01 | 2009-05-27 | 浙江美诺华药物化学有限公司 | 一种齐拉西酮的制备方法 |
JP2010522198A (ja) | 2007-03-19 | 2010-07-01 | アカドイア プハルマセウチカルス インコーポレーテッド | 5−ht2aインバースアゴニスト及びアンタゴニストの抗精神病薬との併用 |
CN102234273B (zh) * | 2010-04-21 | 2015-08-05 | 上海医药工业研究院 | 甲磺酸齐拉西酮半水合物及其制备方法 |
CN102234272A (zh) * | 2010-04-21 | 2011-11-09 | 上海医药工业研究院 | 盐酸齐拉西酮半水合物的制备方法 |
CN107848972B (zh) | 2015-07-20 | 2021-06-18 | 阿卡蒂亚药品公司 | 用于制备n-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐和多晶型c的方法 |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
EP3558311A1 (en) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
CN108239085A (zh) * | 2016-12-26 | 2018-07-03 | 四川科瑞德凯华制药有限公司 | 一种甲磺酸齐拉西酮的纯化及制备方法 |
WO2018200977A1 (en) | 2017-04-28 | 2018-11-01 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
WO2019046167A1 (en) | 2017-08-30 | 2019-03-07 | Acadia Pharmaceuticals Inc. | PIMAVANSERIN FORMULATIONS |
CN112724066B (zh) * | 2021-02-04 | 2022-10-21 | 海南鑫开源医药科技有限公司 | 一种盐酸齐拉西酮中间体中的二卤杂质及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
US5338846A (en) * | 1992-08-26 | 1994-08-16 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt |
US5206366A (en) | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
US5312925A (en) * | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
US5359068A (en) * | 1993-06-28 | 1994-10-25 | Pfizer Inc. | Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one |
PT874834E (pt) | 1995-11-07 | 2001-04-30 | Pfizer | Processos e intermediarios para preparacao de 3-(1-piperazinil)-1,2-benzisotiazole |
UA47467C2 (ru) * | 1996-05-07 | 2002-07-15 | Файзер Інк. | Translated By PlajТРИГИДРАТ МЕЗИЛАТА 5-(2-(4-(1,2-БЕНЗИЗОТИАЗОЛ-3-ИЛ)-1-ПИПЕРАЗИНИЛ)ЭТИЛ)-6-ХЛОР-1,3-ДИГИДРО-2(1Н)-ИНДОЛ-2-ОНА (ЗИПРАЗИДОНА), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ПСИХИЧЕСКИХ РАССТРОЙСТВ |
TW491847B (en) | 1996-05-07 | 2002-06-21 | Pfizer | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
US6150366A (en) * | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
-
2003
- 2003-02-14 UY UY27668A patent/UY27668A1/es not_active Application Discontinuation
- 2003-02-17 SI SI200330811T patent/SI1476162T1/sl unknown
- 2003-02-17 CN CN200910261963A patent/CN101735212A/zh active Pending
- 2003-02-17 AP APAP/P/2004/003103A patent/AP2004003103A0/en unknown
- 2003-02-17 ES ES03702918T patent/ES2283745T3/es not_active Expired - Lifetime
- 2003-02-17 PE PE2003000168A patent/PE20030942A1/es not_active Application Discontinuation
- 2003-02-17 GE GE5684A patent/GEP20074030B/en unknown
- 2003-02-17 AU AU2003206035A patent/AU2003206035A1/en not_active Abandoned
- 2003-02-17 MX MXPA04006993A patent/MXPA04006993A/es not_active Application Discontinuation
- 2003-02-17 KR KR1020047012980A patent/KR100773622B1/ko not_active IP Right Cessation
- 2003-02-17 JP JP2003569202A patent/JP4554938B2/ja not_active Expired - Fee Related
- 2003-02-17 PT PT03702918T patent/PT1476162E/pt unknown
- 2003-02-17 CN CNA038042460A patent/CN1635892A/zh active Pending
- 2003-02-17 OA OA1200400216A patent/OA12774A/en unknown
- 2003-02-17 BR BR0307833-7A patent/BR0307833A/pt not_active IP Right Cessation
- 2003-02-17 UA UA20040806969A patent/UA77057C2/uk unknown
- 2003-02-17 EA EA200400815A patent/EA007866B1/ru not_active IP Right Cessation
- 2003-02-17 NZ NZ534443A patent/NZ534443A/en not_active IP Right Cessation
- 2003-02-17 DK DK03702918T patent/DK1476162T3/da active
- 2003-02-17 WO PCT/IB2003/000642 patent/WO2003070246A1/en active Application Filing
- 2003-02-17 RS YU60404A patent/RS60404A/sr unknown
- 2003-02-17 CA CA002475302A patent/CA2475302C/en not_active Expired - Fee Related
- 2003-02-17 PL PL03372238A patent/PL372238A1/xx not_active Application Discontinuation
- 2003-02-17 DE DE60313289T patent/DE60313289T2/de not_active Revoked
- 2003-02-17 AT AT03702918T patent/ATE359787T1/de active
- 2003-02-17 EP EP03702918A patent/EP1476162B1/en not_active Revoked
- 2003-02-18 GT GT200300040A patent/GT200300040A/es unknown
- 2003-02-18 TW TW092103292A patent/TW200307546A/zh unknown
- 2003-02-18 AR ARP030100527A patent/AR038563A1/es unknown
- 2003-02-18 MY MYPI20030564A patent/MY139523A/en unknown
- 2003-02-19 SV SV2003001485A patent/SV2004001485A/es not_active Application Discontinuation
- 2003-02-20 PA PA20038567001A patent/PA8567001A1/es unknown
-
2004
- 2004-07-05 IS IS7344A patent/IS7344A/is unknown
- 2004-07-29 IL IL163277A patent/IL163277A/en unknown
- 2004-08-04 HR HRP20040711 patent/HRP20040711A2/xx not_active Application Discontinuation
- 2004-08-05 ZA ZA200406276A patent/ZA200406276B/en unknown
- 2004-08-13 CO CO04079019A patent/CO5611138A2/es unknown
- 2004-08-17 MA MA27827A patent/MA27177A1/fr unknown
- 2004-08-19 EC EC2004005239A patent/ECSP045239A/es unknown
- 2004-08-19 TN TNP2004000159A patent/TNSN04159A1/fr unknown
- 2004-09-17 NO NO20043902A patent/NO20043902L/no not_active Application Discontinuation
-
2007
- 2007-05-10 CY CY20071100629T patent/CY1106467T1/el unknown
-
2009
- 2009-05-21 AU AU2009202008A patent/AU2009202008A1/en not_active Ceased
-
2010
- 2010-04-22 NO NO20100584A patent/NO20100584L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200400815A1 (ru) | Контролируемый синтез зипразидона и его композиции | |
EA200401157A1 (ru) | N-аминоацетилпирролидин-2-карбонитрилы и их применение в качестве ингибиторов ddp-iv | |
EA200600594A1 (ru) | Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения | |
EA200300171A1 (ru) | Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения | |
TR200102338T2 (tr) | Siklik ikame edilmiş bağlı pirolokarbazoller ve izoindolonlar. | |
EA200000920A1 (ru) | Производные бициклических гидроксамовых кислот | |
NO20034291D0 (no) | 2-aminopropanolderivater | |
EA200400971A1 (ru) | Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения | |
EA199800290A1 (ru) | (метилсульфонил) фенил-2-(5н)-фураноны в качестве ингибиторов циклооксигеназы-2 | |
EA200100971A1 (ru) | Новые соединения и композиции в качестве ингибиторов протеазы | |
EA200100203A1 (ru) | Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов | |
ATE396993T1 (de) | Tetrahydropyranyl-cyclopentyl- tetrahydropyridopyridin-modulatoren der chemokin- rezeptor-aktivität | |
EA200200912A1 (ru) | Новые производные индолин-2-она, их получение и их применение в качестве лигандов рецепторов окситоцина | |
EA200400708A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
EA200201138A1 (ru) | Пептид, модулирующий рецептор тромбопоэтина | |
EA200100516A1 (ru) | Производные 3,3-биарилпиперидина и 2,2-биарилморфолина | |
ATE270271T1 (de) | Sulfonamidhydroxamate | |
SE9901077D0 (sv) | Novel use | |
EA200101234A1 (ru) | Новые производные аминотиазола, их получение и содержащие их фармацевтические композиции | |
EA200100297A1 (ru) | Моногидрат гидробромида элетриптана | |
EA200100517A1 (ru) | Антагонисты 5ht1 для антидепрессантной терапии | |
EA200501046A1 (ru) | Эсциталопрамгидробромид и способ его получения | |
BRPI0416678A (pt) | pirazolpirimidinas | |
EA200400588A1 (ru) | Линейные основные соединения, имеющие антагонистическую активность в отношении nk-2, и их композиции | |
EA199700223A1 (ru) | Бициклические антагонисты тахикининов, их получение и применение в фармацевтической композиции |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MH4D | Revocation of a eurasian patent in part |
Designated state(s): RU |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |